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history included testicular cancer (mixed germ cells neoplasm) diagnosed in
2008 and treated with monolateral orchiectomy. His paternal grandmother
(F2, I:2) was diagnosed with advanced-stage cHL at the age of 74 years
and died thereafter because of disease progression.
Taking into account data from the Finnish registry [2] and the few available
case-reports [3–6], the two families described in this report allow us to add
some considerations. First, the obligate carrier of Family 2 (F2, II:2) is not
affected by lymphoma (individual currently aged 57 years). This suggests a low
penetrance of the potential predisposing gene mutation, or, alternatively, the co-
existence of additional genetic or environmental factors modifying the genetic
risk. Second, the earlier onset of disease in subsequent generations, as found
in Family 2 (I:2, age 74 years; III:3, age 24 years), supports the concept of dis-
ease anticipation, as previously described in HL families [7]. Third, the presence
of two tumors in patient F2, III:3 is an original finding in the setting of NLPHL
families and might suggest a role for mutations involved in DNA repair.
In conclusion, recent findings on NLPHL families emphasize the impor-
tance of a thorough investigation of family history in patients with this sub-
type of HL and underline the importance of genotyping such cases to
decipher the molecular basis of familial clustering.
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Haploidentical cellular therapy in elderly patients with acute
myeloid leukemia: Description of its use in high risk patients
To the Editor:
Guo et al. reported an innovative approach for the treatment of acute myeloid leu-
kemia (AML) in a 2011 issue of Blood [1]. The report showed for the first time that
the infusion after chemotherapy of peripheral blood stem cells (PBSC) from haploi-
dentical donors significantly improved the outcome in elderly AML patients, without
major toxicities. After an initial engraftment, haploidentical donor cells are rejected
by the host immune response. Indeed, the precise mechanism of action of this cell-
therapy procedure is not fully understood and several mechanisms have been
hypothesized to explain its beneficial effects: (i) donor allogeneic Natural killer
(NK)- or T-cells might exert a direct cytotoxicity on leukemic cells; (ii) a
Figure 1. NLPHL family trees. (a) Pedigree of Family 1. (b) Pedigree of Family 2. Each family member is identified by pedigree number. () females; (w) males; (!)
proband; ( ) obligate carrier; black symbols, patients with HL; slashes through symbols, deceased individuals.
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proinflammatory effect of the allogeneic host–donor interaction might trigger an
autologous antitumor immunity; and (iii) cell-therapy might induce modifications in
leukemic cells or in stromal/vascular cells that ultimately elicit an autologous
immune responses.
So far, the data obtained, Guo et al. have not been confirmed by other
groups worldwide. We recently treated with this protocol three elderly patients
with high-risk AML. Compared to the Chinese experience, the patients were
all affected by high-risk AML. As summarized in Table I, Patient #1 had
treatment-related AML following prolonged chemotherapy (six total lines) for
ovarian cancer and her blasts had a mixed phenotype with complex karyo-
type. Patients #2 and #3 had AML with myelodysplasia-related changes, one
of them (Patient #2) had received four azacitidine courses, with poor
response and worsening of both hematological and clinical conditions.
Institutional ethics approval was obtained for the use of this treatment protocol.
All three patients received an induction regimen (a “317” regimen with mitoxan-
trone and ara-C) followed by the infusion of Granulocyte colony-stimulating Factor
(G-CSF)-mobilized PBSC from haploidentical familial donors, according to the orig-
inal protocol [1]. The potential reactivity of patient T-cells against their haploidentical
counterparts was proved in vitro by mixed lymphocyte reaction. This in vitro reactiv-
ity resulted in vivo in graft-rejection, with detectable microchimerism in only one
patients and absence of acute or chronic Graft versus Host Disease (GVHD) in all
patients. As detailed in Table I, Patient #1 had a partial response, with Bone Mar-
row (BM) blast reduction from 90 to 45%. She then received an intensified salvage
regimen (high-dose ara-C and idarubicin plus cyclosporine to overcome Minimal
Residual Disease (MRD) resistance) [2], followed by a second infusion of haploi-
dentical PBSC. After this cycle, she had a complete hematological recovery, and
the BM aspirate showed complete remission of disease at flow cytometry. Six
weeks later, AML relapsed; the patient was not further treated and died shortly
thereafter. Patient #2 and #3 received 1 infusion of haploidentical PBSC after
induction chemotherapy. Patient #2 was refractory, he refused further treatment
and died few weeks later. Patient #3 achieved Complete Remission (CR); however,
she was unable to receive consolidation therapy due to the development of fungal
endophthalmitis and chronic sinusitis by Fusarium. She completely recovered
within 3 months, with a mild residual chronic renal insufficiency. Despite lack of
consolidation therapy, she is still in CR at 11 months of follow up.
Our observation in high-risk elderly AML patients confirms that infusion of
haploidentical-mobilized PBSC following induction chemotherapy is feasible and safe.
Compared to Guo et al. [1,3], we applied the strategy in AML patients with very unfav-
orable prognosis, two of them previously treated either with multiple chemotherapy
lines or with repeated azacitidine courses. In spite of previous treatments, the haploi-
dentical infusion did not induce acute GVHD. Considering the presenting features, the
achievement of CR in two of three patients was encouraging and somehow unex-
pected, especially for the long-surviving patient who achieved CR after a single course
of chemotherapy followed by haploidentical PBSC infusion. Finally, the two patients
achieving CR had a leukothrombocytopenia duration shorter than one might have
expected, suggesting a possible role of the infused cells in favoring hematopoietic
recovery. We conclude that the “nonengraftment haploidentical cell-therapy” is feasible
also in high-risk and previously treated AML patients, although the real efficacy in this
setting needs to be further investigated [4]. Indeed, based on our preliminary experi-
ence, a prospective trial will be launched soon to evaluate the procedure in elderly
AML patients, including AML secondary to myelodysplasia, either untreated or after
azacytidine, therapy-related AML aswell as de novo AML
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TABLE I. Patients’ Characteristics
Patient #1 Patient #2 Patient #3
Age at treatment 65 76 66
Diagnosis, WHO Therapy related1Mixed phenotype AML AML with myelodysplasia
related changes
AML with myelodysplasia
related changes
Cytogenetics Complex karyotype 46; XY 46; XX
Comorbidity Ovarian Ca, 6 lines of CHT None Obesity
Previous chemotherapy for AML Low dose ara-C16-mercaptopurine Azacitidine None
N. of cycles (with haplo-PBSC) 2 1 1
1 st cycle 2nd cycle 1 st cycle 1 st cycle
N. of CD341 cells infused 13106/Kg 13106/Kg 33106/Kg 2,53106/Kg
N. of CD31 cells infused 0,73108/Kg* 0,73108/Kg 0,863108/Kg 13108/Kg
N. of CD561 cells infused nd nd 0,183108/Kg 0,133108/Kg
Time to ANC>500/mL 19 17 45 11
Time to Plts >50.000/mL 17 18 no recovery for plts 18
Microchimerism Yes Yes No No
GVHD (acute or chronic) No No No No
Transplant related toxicity Neutropenic Fever with Pneumonia Neutropenic fever Neutropenic Fever,
Ototoxicity (amikacina)
Fungal endophtalmitis and
chronic sinusitis
Response after first cycle PR* CR Refractory CR
Survival (from 1st PBSC infusion) 6 months 3 months 10 months
Status at last follow up Dead of disease Dead of disease Alive in CR
* PR defined as: all hematologic criteria of CR and decrease of pretreatment bone marrow blast percentage by at least 50%.
nd: not determined.
correspondence
American Journal of Hematology 721
